APA (7th ed.) Citation

S, P., LG, P., M, R., DP, C., JR, B., H, B., . . . SS, R. (2025). Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 20(1), 94. https://doi.org/10.1016/j.jtho.2024.09.1439

Chicago Style (17th ed.) Citation

S, Peters, et al. "Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis." Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer 20, no. 1 (2025): 94. https://doi.org/10.1016/j.jtho.2024.09.1439.

MLA (9th ed.) Citation

S, Peters, et al. "Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic NSCLC and Tumor Programmed Death-Ligand 1 Lower Than 1%: A Pooled Analysis." Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, vol. 20, no. 1, 2025, p. 94, https://doi.org/10.1016/j.jtho.2024.09.1439.